By writer to www.wdsu.com
Researchers at Tulane College’s College of Drugs have partnered with MDR Logix to develop a therapy for COVID-19.Dr. Jay Kolls, of Tulane College, stated the protein is designed to dam the coronavirus from attacking wholesome cells. He advised WDSU that it has already successfully blocked the virus in cell cultures.Kolls stated the protein is just not a vaccine.”Most vaccines work by inducing your personal immune system to make antibodies,” stated Kolls. “On this case, we’re simply providing you with the antibody, so we’re not ready for the six or eight weeks for the vaccine to take impact.”He stated the therapy can be finest for individuals who can’t get the vaccine as soon as one is developed.”Some sufferers received’t have the ability to get a vaccine,” stated Kolls. “They could be present process chemotherapy for most cancers or possibly they’ve had an organ transplant, like a kidney transplant. They could not make a great response to a vaccine, so this can be a drug that would assist these sorts of sufferers.”Kolls hopes to start a security research for the protein in late fall.
Researchers at Tulane College’s College of Drugs have partnered with MDR Logix to develop a therapy for COVID-19.
Dr. Jay Kolls, of Tulane College, stated the protein is designed to dam the coronavirus from attacking wholesome cells. He advised WDSU that it has already successfully blocked the virus in cell cultures.
Kolls stated the protein is just not a vaccine.
“Most vaccines work by inducing your personal immune system to make antibodies,” stated Kolls. “On this case, we’re simply providing you with the antibody, so we’re not ready for the six or eight weeks for the vaccine to take impact.”
He stated the therapy can be finest for individuals who can’t get the vaccine as soon as one is developed.
“Some sufferers received’t have the ability to get a vaccine,” stated Kolls. “They could be present process chemotherapy for most cancers or possibly they’ve had an organ transplant, like a kidney transplant. They could not make a great response to a vaccine, so this can be a drug that would assist these sorts of sufferers.”
Kolls hopes to start a security research for the protein in late fall.
— to www.wdsu.com
